Compare ATYR & SACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATYR | SACH |
|---|---|---|
| Founded | 2005 | 2010 |
| Country | United States | United States |
| Employees | 58 | 27 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.7M | 46.9M |
| IPO Year | N/A | N/A |
| Metric | ATYR | SACH |
|---|---|---|
| Price | $0.74 | $1.00 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 8 | 3 |
| Target Price | ★ $4.20 | $2.00 |
| AVG Volume (30 Days) | ★ 998.5K | 201.1K |
| Earning Date | 03-05-2026 | 03-12-2026 |
| Dividend Yield | N/A | ★ 20.44% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $150.14 |
| Revenue Next Year | N/A | $4.60 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.64 | $0.80 |
| 52 Week High | $7.29 | $1.35 |
| Indicator | ATYR | SACH |
|---|---|---|
| Relative Strength Index (RSI) | 36.57 | 50.33 |
| Support Level | $0.67 | $0.90 |
| Resistance Level | $0.85 | $1.12 |
| Average True Range (ATR) | 0.05 | 0.05 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 11.12 | 49.76 |
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns the majority of its revenue through Interest income from loans.